Germline mutations in BRCA1, BRCA2, CHEK2 and TP53 in patients at high-risk for HBOC: Characterizing a Northeast Brazilian Population

Human Genome Variation

Volumn 1, Issue , 2014, Pages

  Felix, Gabriela ES ^a,b   Abe Sandes, Camila ^a   Machado Lopes, Taísa MB ^a   Bomfim, Thaís F ^a   Guindalini, Rodrigo Santa Cruz ^a,c   Santos, Vanessa Catarine SAR ^a   Meyer, Lorena ^a   Oliveira, Polyanna C ^a,b   Neiva, João Cláudio ^a   Meyer, Roberto ^a   Romeo, Maura ^a   Toralles, Maria Betânia ^a   Nascimento, Ivana ^a   Abe Sandes, Kiyoko ^a,b  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; DNA; PROTEIN P53;

ADULT; AFRICAN; AMERICAN INDIAN; ARTICLE; BAHIA; BREAST CARCINOMA; DNA DETERMINATION; EUROPEAN; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC HETEROGENEITY; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GERMLINE MUTATION; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; OVARY ADENOCARCINOMA; POPULATION STRUCTURE; PRIORITY JOURNAL;

EID: 84948387036     PISSN: None     EISSN: 2054345X     Source Type: Journal    
DOI: 10.1038/hgv.2014.12     Document Type: Article

References (59)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer Statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Smith EC. An overview of hereditary breast and ovarian cancer syndrome. J Midwifery Womens Health 2012; 57: 577-584.
3. Apoustolou P, Fostira F. Hereditary breast cancer: the era of new susceptibility genes. Biomed Res Int 2013; 2013: 74318.
4. Achatz MIW, Olivier M, Le Calvez F, Martel-Planche G, Lopes A, Rossi BM et al. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett 2007; 245: 96-102.
5. Allinen M M, Huusko P, Mäntyniemi S, Launonen V, Winqvist R. Mutation analysis of the CHEK2 gene in families with hereditary breast cancer. Br J Cancer 2001; 85: 209-212.
6. Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, e TP53 in families at high risk of breast cancer. J Am Med Assoc 2006; 295: 1378-1388.
7. Bordeleau L, Panchal S, Goodwin P. Prognosis of BRCA-associated breast cancer: a summary of evidence. Breast Cancer Res Treat 2010; 119: 13-24.
8. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Eng J Med 1997; 336: 1401-1408.
9. Machado PM, Brandão RD, Cavaco BM, Eugénio J, Bento S, Nave M et al. Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes. J Clin Oncol 2007; 25: 2027-2034.
10. Peixoto A, Santos C, Rocha P, Pinheiro M, Príncipe S, Pereira D et al. The c.156_157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal. Breast Cancer Res Treat 2009; 114: 31-38.
11. Garritano S, Gemignani F, Palmero EI, Olivier M, Martel-Planche G, Le Calvez-Kelm F et al. Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect. Hum Mutat 2010; 31: 143-150.
12. Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 1996; 13: 117-119.
13. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R et al. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002; 31: 55-59.
14. Gilliland FD. Ethnic differences in cancer incidence: a marker for inherited susceptibility? Environ Health Perspect 1997; 105: 897-900.
15. Neuhausen SL. Ethnic differences in cancer risk resulting from genetic variation. Cancer 1999; 86: 2575-2582.
16. Instituto Brasileiro de Geografia e Estatística. Brasil 500 anos de povoamento, Centro de Documentação e Disseminação de Informações IBGE: Rio de Janeiro: Brasil, 2007.
17. Felix GES, Abe Sandes K, Bonfim TM, Bendicho MT, Cisneiros P, Guedes R et al. Ancestry informative markers and complete blood count parameters in Brazilian blood donors. Rev Bras Hematol Hemoter 2010; 32: 282-285.
18. Abe-Sandes K, Bomfim TF, Machado TMB, Abe-Sandes C, Acosta AX et al. Ancestralidade genômica, nível socioeconômico vulnerabilidade ao HIV-aids na Bahia, Brasil. Saúde Soc São Paulo 2010; 19: 75-84.
19. Luizon MR, Mendes-Junior CT, De Oliveira SF, Simões AL. Ancestry informative markers in Amerindians from Brazilian Amazon. Am J Hum Biol 2008; 20: 86-90.
20. Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena SD. Color and genomic ancestry in Brazilians. Proc Natl Acad Sci 2003; 100: 177-182.
21. Santos NP, Ribeiro-Rodrigues EM, Ribeiro-Dos-Santos AK, Pereira R, Gusmão L, Amorim A et al. Assessing individual interethnic admixture and population substructure using a 48-insertion-deletion (INSEL) ancestry-informative marker (AIM) panel. Hum Mutat 2010; 31: 184-190.
22. Friedman L, Ostermeyer EA, Szabo CI, Dowd P, Lynch ED, Rowell SE, King Marie-Claire. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 1994; 8: 399-404.
23. Bayran S, Topaktaş M, Akkız H, Bekar A, Akgöllü E. CHEK2 1100delC, IVS2+1G4A and I157T mutations are not present in colorectal cancer cases from Turkish population. Cancer Epidemiol 2012; 36: 453-457.
24. Custodio G, Taques GR, Figueiredo BC, Gugelmin ES, Oliveira Figueiredo MM, Watanabe F et al. Increased incidence of choroid plexus carcinoma due to the germline TP53 R337H mutation in Southern Brazil. PLoS ONE 2011; 6: e18015.
25. Parra EJ, Marcini A, Akey J, Martinson J, Batzer MA, Cooper R et al. Estimating African American admixture proportions by use of population-specific alleles. Am J Hum Genet 1998; 63: 1839-1851.
26. Shriver MD, Parra EJ, Dios S, Bonilla C, Norton H, Jovel C et al. Skin pigmentation, biogeographical ancestry and admixture mapping. Hum Genet 2003; 112: 387-399.
27. Raymond M, Rousset F. GENEPOP (version 1.2): population genetics software for exact tests and ecumenicism. J Hered 1995; 86: 248-249.
28. Chakraborty R. Gene identity in racial hybrids and estimation of admixture rates. In: Ahuja YR, Neel JV (eds). Genetic Differentiation in Human and other Animal Populations. Indian Anthropological Association: Delhi 1985: 171-180.
29. Falush D, Stephens M, Pritchard JK. Inference of population structure using multilocus genotype data: dominant markers and null alleles. Mol Eco Notes 2007; 7: 574-578.
30. Blay P, Santamaría I, Pitiot AS, Luque M, Alvarado MG, Lastra A et al. Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain). BMC Cancer 2003; 13: 243.
31. Rodríguez AO, Pardo GG, Royer R, Larson G, Weitzel JN et al. BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia. Gynecol Oncol 2012; 124: 236-243.
32. Blesa JR, García JA, Ochoa E. Frequency of germ-line BRCA1 mutations among Spanish families from a Mediterranean area. Hum Mut 2000; 15: 381-382.
33. Lourenço JJ, Vargas FR, Bines J, Santos EM, Lasmar CAP, Costa CH et al. BRCA1 mutations in Brazilian patients. Genet Mol Biol 2004; 27: 500-504.
34. Esteves VF, Thuler LC, Amêndola LC, Koifman RJ, Koifman S, Frankel PP et al. Prevalence of BRCA1 and BRCA2 gene mutations in families with medium and high risk of breast and ovarian cancer in Brazil. Braz J Med Biol Res 2009; 42: 453-457.
35. Vega A, Campos B, Bressac-De-Paillerets B, Bond PM, Janin N, Douglas FS et al. The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript. Hum Mutat 2001; 17: 520-521.
36. Salas A, Comas D, Lareu MV, Bertranpetit J, Carracedo A. mtDNA analysis of the Galician population: a genetic edge of the European variation. Eur J Hum Genet 1998; 6: 365-375.
37. Santos C, Peixoto A, Rocha P, Vega A, Soares MJ, Cerveira N et al. Haplotype and quantitative transcript analyses of Portuguese breast/ovarian cancer families with the BRCA1 R71G founder mutation of Galician origin. Fam Cancer 2009; 8: 203-208.
38. John EM, Miron A, Gong G, Phipps AI, Felberg A, Li FP, West DW, Whittemore AS. Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. J Am Med Assoc 2007; 298: 2869-2876.
39. Weitzel JN, Lagos V, Blazer KR, Nelson R, Ricker C, Herzog J et al. Prevalence of BRCA mutations and founder effect in high-risk hispanic families. Cancer Epidemiol Biomark Prev 2005; 14: 1666-1671.
40. Bacelar JA. Galegos no Paraíso Racial. Centro Editorial e Didático da UFBA. IANAMÁ: Salvador, Brasil, 1994.
41. Leira LP. Galegos na Bahia de todos os SantosGalicia en El Mundo Edicións. Editora Graciela Alba Burgos: Spain 2002: 10-22.
42. Zhang L, Fleischut MH, Kohut K, Spencer S, Wong K, Stadler ZK et al. Assessment of the prevalence of de novo mutations in the BRCA1 and BRCA2 genes. Clin Genet 2011; 80: 97-98.
43. Ashton-Prolla P, Osorio CABT, Khoeler-Santos P, Graudenz MS, Palmero EI, Fernandes G et al. Contribution of TP53 p.R337H mutation to breast cancer prevalence in Brazil. J Clin Oncol 2012; (suppl 30): (abstr 1522).
44. Assumpção JG, Seidinger AL, Mastellaro MJ, Ribeiro RC, Zambetti GP, Ganti R et al. Association of the germline TP53 R337H mutation with breast cancer in southern Brazil. BMC Cancer 2008; 11: 152.
45. Gomes MCB, Kotsopoulos J, de Almeida GL, Costa MM, Vieira R, Filho Fde A et al. The R337H mutation in TP53 and breast cancer in Brazil. Hered Cancer Clin Pract 2012; 10: 3.
46. NCCN - National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology™. Genetic/Familial High-Risk Assessment: Breast and Ovarian, Hereditary Breast and/or Ovarian Cancer (HBOC-1) V.1; 2010. www.nccn.org.
47. ®Johns Hopkins University, Baltimore, MD. MIM Number: #151623. http://omim.org/. Accessed 4 January 2013.
48. Cury NM, Ferraz VE1, Silva WA Jr. TP53 p.R337H prevalence in a series of Brazilian hereditary breast cancer families. Hered Cancer Clin Pract 2014; 12: 8.
49. McCuaig JM1, Armel SR, Novokmet A, Ginsburg OM, Demsky R, Narod AS et al. Routine TP53 testing for breast cancer under age 30: ready for prime time? Fam Cancer 2012; 11: 607-613.
50. Gomes MC, Costa MM, Borojevic R, Monteiro AN, Vieira R, Koifman S, Koifman RJ et al. Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. Breast Cancer Res Treat 2007; 103: 349-353.
51. Ewald IP, Izetti P, Vargas FR, Moreira MA, Moreira AS, Moreira-Filho CA et al. Prevalence of the BRCA1 founder mutation c.5266dupin Brazilian individuals at-risk for the hereditary breast and ovarian cancer syndrome. Hered Cancer Clin Pract 2011; 9: 12.
52. Carraro DM, Folgueira MAAK, Lisboa BCG, Olivieri EHR, Krepischi ACV, Carvalho AF et al. Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: a portrait of early-onset breast cancer in Brazil. PLoS ONE 2013; 8: e57581.
53. Dillenburg CV, Bandeira IC, Tubino TV, Rossato LG, Dias ES, Bittelbrunn AC et al. Prevalence of 185delAG and 5382insC mutations in BRCA1, and 6174delT in BRCA2 in women of Ashkenazi Jewish origin in southern Brazil. Genet Mol Biol 2012; 35: 599-602.
54. Hamel N, Feng BJ, Foretova L, Stoppa-Lyonnet D, Narod SA, Imyanitov E et al. On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations. Eur J Hum Genet 2011; 19: 300-306.
55. Levy MSF. O papel da migração internacional na evolução da população brasileira (1872 a 1972). Rev de Saúde Pública 1974; 3: 49-90.
56. Moreira MAM, Bobrovnitchaia IG, Lima MA, Santos AC, Ramos JP, Souza KR et al. Portuguese c.156_157insAlu BRCA2 founder mutation: gastrointestinal and tongue neoplasias may be part of the phenotype. Fam Cancer 2012; 11: 657-660.
57. Cybulski C, Górski B, Huzarski T, Masojć B, Mierzejewski M, Debniak T et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 2004; 75: 1131-1135.
58. Abud J, Prolla JC, Rossi C, Palmero EI, Vargas FR, Nunes LM et al. CHEK2 1100DELC germline mutation: a frequency study in hereditary breast and colon cancer Brazilian families. Arq Gastroenterol 2012; 49: 273-278.
59. Azevêdo E, Fortuna CM, Silva KM, Sousa MG, Machado MA, Lima AM et al. Spread and diversity of human populations in Bahia, Brazil. Hum Biol 1982; 54: 329-341.